<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Takeda Exploits Avandia Woes With New Ads</title>
	<atom:link href="http://www.pharmalot.com/2007/11/takeda-exploits-avandia-woes-with-new-ads/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2007/11/takeda-exploits-avandia-woes-with-new-ads/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 21:22:05 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Pharma News 11_16 &#171; Impactiviti blog</title>
		<link>http://www.pharmalot.com/2007/11/takeda-exploits-avandia-woes-with-new-ads/#comment-26348</link>
		<dc:creator>Pharma News 11_16 &#171; Impactiviti blog</dc:creator>
		<pubDate>Fri, 16 Nov 2007 02:30:19 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2007/11/takeda-exploits-avandia-woes-with-new-ads/#comment-26348</guid>
		<description>[...] GSK&#8217;s Avandia woes deepening, Takeda is about to launch an advertising blitz for Actos. Meanwhile, GSK experiments with new selling models (including fewer sales reps, of [...]</description>
		<content:encoded><![CDATA[<p>[...] GSK&#8217;s Avandia woes deepening, Takeda is about to launch an advertising blitz for Actos. Meanwhile, GSK experiments with new selling models (including fewer sales reps, of [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.146 seconds -->

